Somatostatin receptor subtype 2 A (SSTR2A) and HER2 expression in gastric adenocarcinoma

Adriana Romiti, Roberta Di Rocco, Massimo Milione, Luigi Ruco, Vincenzo Ziparo, Angelo Zullo, Enrico Duranti, Ida Sarcina, Viola Barucca, Chiara D'Antonio, Paolo Marchetti

Research output: Contribution to journalArticlepeer-review


Background: A possible anticancer role for somatostatin has been suggested. This study assessed the presence of somatostatin receptor subtype 2A (SSTR2A) in gastric cancer, correlating its expression with histological type, grade, human epidermal growth factor receptor 2 (HER2) expression, and disease outcome. Materials and Methods: Gastric cancer tissues of 51 consecutive patients were collected for immunohistochemical assessment of both SSTR2A and HER2 expression. Results: SSTR2A expression was observed in 38 (74.5%) cases. Prevalence of SSTR2A expression was significantly higher in well to moderately (G1-2) differentiated gastric cancer as compared to poorly (G3) differentiated tumors (96% vs. 52%; p

Original languageEnglish
Pages (from-to)115-119
Number of pages5
JournalAnticancer Research
Issue number1
Publication statusPublished - Jan 2012


  • Gastric cancer
  • HER2
  • Somatostatin receptor 2A
  • SSTR2A

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Somatostatin receptor subtype 2 A (SSTR2A) and HER2 expression in gastric adenocarcinoma'. Together they form a unique fingerprint.

Cite this